18.03.2016 • NewsDede WillamsPeopleAndrew Witty

GSK’s Witty Names Retirement Date

It’s official. Andrew Witty, CEO of Britain’s largest drugmaker, Glaxo SmithKline (GSK), has announced he will retire in March 2017 after nearly a decade at the helm.

In a statement, the CEO said he believes a year from now “will be the right time for a new leader to take over.”

Even before the announcement, the search for a successor was thought to be well underway. Witty has been under pressure from investors to boost profits or break up the company into smaller units.

According to news agencies, the company’s board of directors recently appointed headhunters Egon Zehnder and Korn Ferry to find a new chief.

Along with the challenges from generic competitors faced by many other large drugmakers, Witty has come under fire from GSK shareholders who have been clamoring for a new blockbuster to replace drugs with expiring patents.

GSK has also been embroiled in a bribery probe and faced a fine of £37.6 million for delaying the market entry of generic competition for the company’s anti-depressant Seroxat.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.